Johnson & Johnson (J&J) has expanded its partnership with the US Department for Health and Human Service (HSS)’s Biomedical Advanced Research and Development Authority (BARDA) to commit more than $1bn to co-fund research and development (R&D), as well as clinical testing, of Covid-19 vaccines.
This builds upon an existing partnership between J&J and BARDA to develop anti-viral drugs against the novel coronavirus. This part of the partnership will also receive additional funding; the precise amount was not disclosed.
Go deeper with GlobalData
J&J chairman and CEO Alex Gorsky said: “The world is facing an urgent public health crisis and we are committed to doing our part to make a COVID-19 vaccine available and affordable globally as quickly as possible.
“As the world’s largest healthcare company, we feel a deep responsibility to improve the health of people around the world every day.”
Read the full story here.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
